171 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Gilbert, P. B., Montefiori, D. C., McDermott, A., Fong, Y., Benkeser, D. C., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O’Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., … Teams, U. S. G. (USG)/CoVPN B. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. MedRxiv, 2021.08.09.21261290. https://doi.org/10.1101/2021.08.09.21261290

    1. Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

    1. Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

  2. Apr 2022
    1. Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., Tipton, T., Hering, L. M., Angyal, A., Brown, R., Nicols, A. R., Gillson, N., Dobson, S. L., Amini, A., Supasa, P., … Zawia, A. A. T. (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 184(23), 5699-5714.e11. https://doi.org/10.1016/j.cell.2021.10.011

    1. Ravi K Gupta [@ravgup33_ravi]. (2021, November 24). This one is worrying and I’ve not said that since delta. Please get vaccinated and boosted and mask up in public as the mutations in this virus likely result in high level escape from neutralising antibodies [Tweet]. Twitter. https://twitter.com/ravgup33_ravi/status/1463626745651806208

  3. Mar 2022
    1. Lauren Pelley. (2022, February 24). BREAKING: Made-in-Canada #COVID19 vaccine from Medicago approved by Health Canada today. Shot dubbed ‘Covifenz,’ and uses virus-like particles. Background on the high efficacy against infection seen during Phase 3 clinical trials: Https://t.co/5clkYzatVK [Tweet]. @LaurenPelley. https://twitter.com/LaurenPelley/status/1496859590402654208

  4. Feb 2022
  5. Jan 2022
    1. Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J., Wolf, C., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., Briggs-Hagen, M., Saydah, S., Midgley, C. M., Pringle, K., Chu, H., Bloom, J. D., & Englund, J. A. (2022). Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time (p. 2022.01.14.22269235). medRxiv. https://doi.org/10.1101/2022.01.14.22269235

    1. Liu, Y., Ebinger, J. E., Mostafa, R., Budde, P., Gajewski, J., Walker, B., Joung, S., Wu, M., Bräutigam, M., Hesping, F., Rupieper, E., Schubert, A.-S., Zucht, H.-D., Braun, J., Melmed, G. Y., Sobhani, K., Arditi, M., Van Eyk, J. E., Cheng, S., & Fert-Bober, J. (2021). Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. Journal of Translational Medicine, 19(1), 524. https://doi.org/10.1186/s12967-021-03184-8

  6. Dec 2021
    1. Garcia-Beltran, W. F., Denis, K. J. S., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., Feldman, J., Gregory, D. J., Poznansky, M. C., Schmidt, A. G., Iafrate, A. J., Naranbhai, V., & Balazs, A. B. (2021). MRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (p. 2021.12.14.21267755). https://doi.org/10.1101/2021.12.14.21267755

  7. Nov 2021
    1. ReconfigBehSci. (2021, November 1). 2/2 from the paper ‘We speculate that the extraordinarily high antibody titers observed in vaccinated individuals who develop breakthrough infections may lead to subsequent long-term protection in those individuals.’ [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1455104597454954497

  8. Oct 2021
    1. Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., Giglioli, G., De Santi, C., Fabbiani, M., Rancan, I., Tumbarello, M., Montagnani, F., Sala, C., Montomoli, E., & Rappuoli, R. (2021). Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 1–7. https://doi.org/10.1038/s41586-021-04117-7

    1. Prof. Akiko Iwasaki. (2021, September 23). Thankfully, we have not seen any evidence of antibody-dependent enhancement of infection or disease by any COVID vaccines to date. Vaccine are not making infections worse, and are very effective in preventing disease. [Tweet]. @VirusesImmunity. https://twitter.com/VirusesImmunity/status/1441074260534075392

  9. Sep 2021
    1. John Burn-Murdoch. (2021, August 23). NEW: in the last couple of weeks there have a lot of new studies out assessing vaccine efficacy, many of which have touched on the question of waning immunity. Unsurprisingly, these have prompted a lot of questions. Time for a thread to summarise what we do and don’t know: [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1429878189011111936

  10. Aug 2021
    1. Liu, Y., Arase, N., Kishikawa, J., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., Jin, H., Kishida, K., Nakai, W., Kohyama, M., Nakagawa, A., Yamagishi, Y., Nakagami, H., Kumanogoh, A., Matsuura, Y., … Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (p. 2021.08.22.457114). https://doi.org/10.1101/2021.08.22.457114

    1. Madhi, S. A., Koen, A. L., Izu, A., Fairlie, L., Cutland, C. L., Baillie, V., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Aley, P. K., Bhikha, S., Hermanus, T., Horne, E., Jose, A., Kgagudi, P., Lambe, T., Masenya, M., … Kwatra, G. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. The Lancet HIV, 0(0). https://doi.org/10.1016/S2352-3018(21)00157-0

    1. Hillus, David, Tatjana Schwarz, Pinkus Tober-Lau, Hana Hastor, Charlotte Thibeault, Stefanie Kasper, Elisa T. Helbig, et al. “Safety, Reactogenicity, and Immunogenicity of Homologous and Heterologous Prime-Boost Immunisation with ChAdOx1-NCoV19 and BNT162b2: A Prospective Cohort Study,” June 2, 2021. https://doi.org/10.1101/2021.05.19.21257334.

    1. Prof. Devi Sridhar. “Rest of the World Watching Closely: ‘In Scotland, Estimated That 92.5% of Adults Would Have Tested Positive for Antibodies against SARS-CoV-2 on a Blood Test in the Week Beginning 12 July 2021’- Is This Enough to Dampen Transmission & Protect under 12s from Infection? Under 18s?” Tweet. @devisridhar (blog), August 4, 2021. https://twitter.com/devisridhar/status/1422852550957617157.

    1. Tenbusch, M., Schumacher, S., Vogel, E., Priller, A., Held, J., Steininger, P., Beileke, S., Irrgang, P., Brockhoff, R., Salmanton-García, J., Tinnefeld, K., Mijocevic, H., Schober, K., Bogdan, C., Yazici, S., Knolle, P., Cornely, O. A., Überla, K., Protzer, U., … Wytopil, M. (2021). Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00420-5

  11. Jul 2021
    1. Elisabeth Mahase. (2021, July 26). At least 6 weeks between Pfizer vaccine doses = higher neutralising antibody levels (than a 3-4 wk interval) For those with the delta variant, antibody levels were 2.3-fold higher with the longer interval Preprint from @pitchstudy @bmjlatest https://t.co/E3yOTqNgpa [Tweet]. @emahase. https://twitter.com/emahase_/status/1419604658344112130

  12. Jun 2021
    1. Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

  13. May 2021
    1. Jonathan Rothberg 🦋. (2021, March 2). Testing works. I test daily. Insist on HOME testing. @michaelmina_lab @JoeBiden Research suggests B.1.526 needs to be closely watched “for its ability to evade both monoclonal antibody and, to a certain extent, the vaccine-induced antibody,” said Fauci [Tweet]. @JMRothberg. https://twitter.com/JMRothberg/status/1366755339912306688

  14. www.imperial.ac.uk www.impe